Official Title
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Brief Summary

This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection.

Detailed Description

This is a single center, prospective, observational cohort study. A total of 50 cases who are

novel coronavirus (COVID-19) positive will be recruited. Presenting to the emergency room of

the study site, these cases will be treated with N-acetylglucosamine (NAG) (700 mg every 12

hours) as first-line treatment for 30 days. Standard of care (e.g., Remdesivir approved for

emergency use in severe cases, ventilator for patients with respiratory failure, etc.) will

be provided based on the patient's clinical needs, which will be at the discretion of the

treating physician. The results of the patient's blood work (e.g. complete blood count,

C-reactive protein [CRP], procalcitonin [PCT], IL-6, erythrocyte sedimentation rate [ESR],

etc.), symptom progression, clinical severity, and outcomes will be collected on a daily

basis during hospitalization until. The primary outcomes of interest are rates of intubation,

mortality, and length of stay (LOS) following rapid administration of 700 mg NAG for

COVID-19-related symptoms. Secondary outcomes of interest include: change in COVID-19 disease

severity as assessed by the WHO Ordinal Scale for Clinical Improvement; symptom duration; ICU

admission; supplemental oxygen use and duration; and change in inflammatory biomarker levels

(CRP, PCT, IL-6, ESR). Finally, the safety profile of NAG was evaluated using patient medical

records from Day 1 through discharge.

Active, not recruiting

Dietary Supplement: N-acetyl glucosamine (NAG)
Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
N-Acetyl Glucosamine

Eligibility Criteria

Inclusion Criteria: - ≥18 years old - Treated with NAG as first-line treatment - Present with COVID-19 symptoms (including but not limited to fever, cough, shortness of breath, sore throat, nasal congestion, malaise, headache, muscle pain, loss of taste and/or smell, diarrhea, and vomiting) - Clinically diagnosed with COVID-19 by RT-PCR - No intubation prior to hospitalization and enrollment in the current study.

Exclusion Criteria: -

Eligibility Gender
Eligibility Age
Minimum: 18 Years
United States

Valley Baptist Medical Center
Harlingen, Texas, 78550 LLC
NCT Number
N-acetyl glucosamine
MeSH Terms
Coronavirus Infections